KR102991384B1 - 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) - Google Patents
조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis)Info
- Publication number
- KR102991384B1 KR102991384B1 KR1020227039203A KR20227039203A KR102991384B1 KR 102991384 B1 KR102991384 B1 KR 102991384B1 KR 1020227039203 A KR1020227039203 A KR 1020227039203A KR 20227039203 A KR20227039203 A KR 20227039203A KR 102991384 B1 KR102991384 B1 KR 102991384B1
- Authority
- KR
- South Korea
- Prior art keywords
- triiodothyronine
- sepsis
- pharmaceutical composition
- administration
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20200100200 | 2020-04-21 | ||
| GR20200100200A GR1010068B (el) | 2020-04-21 | 2020-04-21 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο |
| GR20200100695 | 2020-11-23 | ||
| GR20200100695A GR1010182B (el) | 2020-11-23 | 2020-11-23 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας |
| GR20210100216 | 2021-03-29 | ||
| GR20210100216A GR1010261B (el) | 2021-03-29 | 2021-03-29 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης |
| PCT/GR2021/000019 WO2021214497A1 (en) | 2020-04-21 | 2021-04-15 | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230022839A KR20230022839A (ko) | 2023-02-16 |
| KR102991384B1 true KR102991384B1 (ko) | 2026-07-14 |
Family
ID=76197481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227039203A Active KR102991384B1 (ko) | 2020-04-21 | 2021-04-15 | 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12673036B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138810A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023538984A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102991384B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115996710B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021258544A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021250A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3176106A1 (cg-RX-API-DMAC7.html) |
| GE (2) | GEP20247706B (cg-RX-API-DMAC7.html) |
| IL (1) | IL297398B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013228A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021214497A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202212502B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20247706B (en) | 2020-04-21 | 2024-12-10 | Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024919A1 (en) * | 1994-03-15 | 1995-09-21 | K.U. Leuven Research & Development | New use of growth hormone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571840A (en) | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
| US20050059574A1 (en) | 2000-12-21 | 2005-03-17 | Irwin Klein | Compositions of stable T3 and methodes of use thereof |
| JP2004525874A (ja) | 2000-12-21 | 2004-08-26 | リサスサイテック, インコーポレイテッド | 安定したt3の組成物およびその使用方法 |
| US8404281B2 (en) | 2009-06-08 | 2013-03-26 | Avant Garde Therapeutics & Technologies Llc | Formulations |
| CN103705497B (zh) | 2013-12-11 | 2015-04-01 | 武汉威立得生物医药有限公司 | 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用 |
| KR102149321B1 (ko) | 2015-10-31 | 2020-08-28 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| EP3908272B1 (en) | 2019-01-09 | 2023-03-22 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | L-triiodothyronine (t3) for use in limiting microvascular obstruction |
| GEP20247706B (en) | 2020-04-21 | 2024-12-10 | Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis |
| GR1010182B (el) | 2020-11-23 | 2022-03-01 | Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας |
| GR1010068B (el) | 2020-04-21 | 2021-09-01 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο |
-
2021
- 2021-04-15 GE GEAP202116094A patent/GEP20247706B/en unknown
- 2021-04-15 CN CN202180029865.9A patent/CN115996710B/zh active Active
- 2021-04-15 AU AU2021258544A patent/AU2021258544A1/en active Pending
- 2021-04-15 US US17/920,171 patent/US12673036B2/en active Active
- 2021-04-15 MX MX2022013228A patent/MX2022013228A/es unknown
- 2021-04-15 IL IL297398A patent/IL297398B2/en unknown
- 2021-04-15 JP JP2022563957A patent/JP2023538984A/ja active Pending
- 2021-04-15 CA CA3176106A patent/CA3176106A1/en active Pending
- 2021-04-15 EP EP21728969.3A patent/EP4138810A1/en active Pending
- 2021-04-15 BR BR112022021250A patent/BR112022021250A2/pt unknown
- 2021-04-15 KR KR1020227039203A patent/KR102991384B1/ko active Active
- 2021-04-15 GE GEAP202416094A patent/GEAP202416094A/en unknown
- 2021-04-15 WO PCT/GR2021/000019 patent/WO2021214497A1/en not_active Ceased
-
2022
- 2022-11-16 ZA ZA2022/12502A patent/ZA202212502B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024919A1 (en) * | 1994-03-15 | 1995-09-21 | K.U. Leuven Research & Development | New use of growth hormone |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022021250A2 (pt) | 2022-12-06 |
| ZA202212502B (en) | 2024-05-30 |
| IL297398B2 (en) | 2026-05-01 |
| IL297398B1 (en) | 2026-01-01 |
| IL297398A (en) | 2022-12-01 |
| KR20230022839A (ko) | 2023-02-16 |
| US12673036B2 (en) | 2026-07-07 |
| GEP20247706B (en) | 2024-12-10 |
| US20230157982A1 (en) | 2023-05-25 |
| AU2021258544A1 (en) | 2022-10-27 |
| MX2022013228A (es) | 2022-11-14 |
| WO2021214497A1 (en) | 2021-10-28 |
| CN115996710B (zh) | 2024-06-28 |
| EP4138810A1 (en) | 2023-03-01 |
| CA3176106A1 (en) | 2021-10-28 |
| JP2023538984A (ja) | 2023-09-13 |
| GEAP202416094A (en) | 2024-07-10 |
| CN115996710A (zh) | 2023-04-21 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |